Colloidal drug carriers: Achievements and perspectives

Cellular and Molecular Life Sciences

Volumn 60, Issue 1, 2003, Pages 21-37

  Barratt, G ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Drug delivery; Liposome; Nanocapsule; Nanoparticle; Nanosphere; Poly(ethylene glycol); Polymer; Targeting

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPICILLIN; ANTIGEN; COPOLYMER; DICLOFENAC; DOXORUBICIN; DRUG CARRIER; GENE PRODUCT; INDOMETACIN; INORGANIC COMPOUND; INSULIN; LIPID; LIPOPROTEIN; LIPOSOME; METAL OXIDE; MURAMYL PEPTIDE; MURAMYLTRIPEPTIDE CHOLESTEROL; MURAMYLTRIPEPTIDE PHOSPHATIDYLETHANOLAMINE; NANOCAPSULE; NANOPARTICLE; NIOSOME; OLIGONUCLEOTIDE; PEPTIDE DERIVATIVE; POLY(CYANOACRYLATE); POLY(METHYLIDENE MALONATE); POLYCAPROLACTONE; POLYSACCHARIDE; PROTEIN DERIVATIVE; SILICON DIOXIDE; STEALTH; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL INFECTION; BIOMIMETICS; BRAIN; CELL; CELL POPULATION; COLLOID; DRUG CLASSIFICATION; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; GASTROINTESTINAL SYMPTOM; GENE TARGETING; HUMAN; HYPOGLYCEMIA; IMMUNIZATION; INFECTION; INFLAMMATION; ISCHEMIA; KAPOSI SARCOMA; KINETICS; KLEBSIELLA PNEUMONIAE; LEUKEMIA; LIVER CELL; LIVER METASTASIS; LUNG METASTASIS; LYSOSOME; MACROPHAGE; MICROEMULSION; MONONUCLEAR PHAGOCYTE; NONHUMAN; PARASITOSIS; PHAGOCYTE; REVIEW; SIDE EFFECT; TISSUE; TOXICITY; TUMOR CELL; VASCULAR ENDOTHELIUM;

BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE;

EID: 0037275061     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180300002     Document Type: Review

References (165)

1. Barratt G., Courraze G., Couvreur P., Dubernet C., Fattal E., Grey R. et al. (2002) Polymeric micro and nanoparticles as drug carriers. In: Polymeric Biomaterials, 2nd ed, pp. 753-782, Dumitriu S. (ed.), Dekker, New York
2. Gregoriadis G., Leathwood P. D. and Ryman B. E. (1971) Enzyme entrapment in liposomes. FEBS Lett. 14: 95-99
3. Gregoriadis G. (1993) Liposome Technology, 2nd Edition, vol. I, CRC, Boca Raton, Fla.
4. Uchegbu I. F. and Florence A. T. (1995) Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. Colloid. Interf. Sci. 58: 1-55
5. Legrand P., Barratt G., Mosqueira V., Fessi H. and Devissaguet J.-P. (1999) Polymeric nanocapsules as drug delivery systems: a review. Sci. Tech. Pharm. 9: 411-418
6. Rensen P. C., Vrueh R. L. de, Kuiper J., Bijsterbosch M. K., Biessen E. A. and Berkel T. J. van (2001) Recombinant lipoproteins: lipoprotein-like particles for drug targeting. Adv. Drug Deliv. Rev. 47: 251-276
7. De Miguel I., Imbertie L., Rieumajou V., Major M., Kravtzoff R. and Betbeder D. (2000) Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm. Res. 17: 817-824
8. Humberstone A. J. and Charman W. N. (1997) Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25: 103-128
9. Poste G., Kirsh R. and Koestler T. (1984) The challenge of liposome targeting in vivo. In: Liposome Technology, 1st ed, vol. III, pp 2-28, Gregoriadis G. (ed.), CRC, Boca Raton
10. Daemen T., Velinova M. J., Regts J., Jager M. de, Kalicharan R., Donga J. et al. (1997) Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology 26: 416-423
11. Romero E. L., Morilla M.-J., Regts J., Koning G. A. and Scherphof G. L. (1999) On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 448: 193-196
12. Senior J. H. (1987) Fate and behaviour of liposomes in vivo: a review of controlling factors. Crit. Rev. Drug. Carrier Syst. 3: 123-193
13. Juliano R. L. (1988) Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Deliv. Rev. 2: 31-54
14. 14C-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13: 1093-1102
15. Scherphof G., Damen J. and Hoekstra D. (1981) Interactions of liposomes with plasma proteins and components of the immune system. In: Liposomes: from Physical Structure to Therapeutic Applications, pp. 299-322, Knight G. (ed.), Elsevier, Amsterdam
16. Woodley J. F. (1986) Liposomes for oral administration of drugs. Crit. Rev. Drug Carrier Syst. 2: 1-18
17. 14C-poly-(D,L-lactic acid) nanoparticles coated with human serum albumin or polyvinyl alcohol to guinea pigs. J. Drug Target. 6: 293-307
18. Devissaguet J.-P., Fessi H., Ammoury N. and Barratt G. (1992) Colloidal drug delivery systems for gastrointestinal applications. In: Drug Targeting and Delivery - Concepts in Dosage Form Design, pp. 79-91, Junginger H. E. (ed.), Horwood, Chichester
19. Eldridge J. H., Hammond C. J., Meulbroek J. A., Staats J. K., Gilley R. M. and Tice T. R. (1990) Controlled vaccine released in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 11: 205-214
20. Jani P., McCarthy D. E. and Florence, A. T. (1992) Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose. Int. J. Pharm. 86: 239-246
21. Ponchel G. and Irache J.-M. (1998) Specific and nonspecific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34: 191-219
22. Lehr C. M. (2000) Lectin-mediated drug delivery: the second generation of bioadhesives. J. Control. Release 65: 19-29
23. Dawson G .F. and Halbert G. W. (2000) In vitro cell association of invasin coated polylactic-co-glycolide nanoparticles. Pharm. Res. 17: 1420-1425
24. Mezei M. (1988) Liposomes in the topical applications of drugs: a review. In: Liposomes as Drug Carriers, pp. 663-677, Gregoriadis, G. (ed.), Wiley, New York
25. Hawley A. E., Davis S. S. and Illum L. (1995) Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv. Drug Deliv. Rev. 17: 129-148
26. Maincent P., Thouvenot P., Amicabile C., Hoffman M., Kreuter J., Couvreur P. et al. (1992) Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm. Res. 9: 1534-1539
27. Nishioka Y. and Yoshino H. (2001) Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 47: 55-64
28. Calvo P., Vila-Jato J. L. and Alonso M. J. (1997) Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int. J. Pharm. 153: 41-50
29. Fidler I . J., Sone S., Fogler W. E. and Barnes Z. L. (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl. Acad. Sci. USA 78: 1680-1684
30. Daemen T., Dontje B. H., Veninga A., Scherphof G. L. And Oosterhuis W. L. (1990) Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. Select. Cancer Ther. 6: 63-71
31. Barratt G. M., Puisieux F., Yu W.-P., Foucher C., Fessi H. and Devissaguet J.-P. (1994) Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. Int. J. Immunopharm. 16: 457-461
32. Asano T. and Kleinerman E. S. (1993) Liposome-entrapped MTP-PE, a novel biologic agent for cancer therapy. J. Immunother. 14: 286-292
33. Melissen P. M. B., Vianen W. van and Bakker-Woudenberg, I. A. J. M. (1994) Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine. Antimicrob. Agents Chemother. 38: 147-150
34. Pinto-Alphandary H., Andremont A. and Couvreur P. (2000) Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 13: 155-168
35. Gregoriadis G. (1994) The immunological adjuvant and vaccine carrier properties of liposomes. J. Drug Target. 2: 351-356
36. Boeckler C., Dautel D., Schelté P., Frisch B., Wachsmann D., Klein J. P. et al. (1999) Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes. Eur. J. Immunol. 29: 2297-2308
37. Gregoriadis G., Saffie R. and Hart S. L. (1996) High yield incorporation of plasmid DNA within liposomes: effect of DNA integrity and transfection efficiency. J. Drug Target. 3: 469-475
38. Gabizon A. (1992) Selective turnout localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52: 891-896
39. Verdun C., Brasseur F., Vranckx H., Couvreur P. and Roland M. (1990) Tissue distribution of doxorubicin associated with polyisohexyl-cyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26: 13-18
40. Daemen T., Regts J., Meesters M., Ten Kate M. T., Bakker-Woudenberg I. A. J. M. and Scherphof G. (1997)Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release 44: 1-9
41. Fernandez-Urrusuno R., Fattal E., Rodrigues J. M. Jr, Féger J., Bedossa P. and Couvreur P. (1996) Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res. 31: 401-408
42. Fawaz F., Bonini F., Guyot M., Lagueny A. M., Fessi H. and Devissaguet J.-P. (1993) Influence of poly(DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm. Res. 10: 750-766.
43. Gibaud S., Andreux J. P., Weingarten C., Renard M. and Couvreur P. (1994) Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer 30A: 820-826
44. Gibaud S., Rousseau C., Weingarten C., Favier R., Douay L., Andreux J. P. et al. (1998) Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte colony stimulating factor (G-CSF). J. Control. Release 52: 131-139
45. Chiannikulchai N., Driouich Z., Benoit J.P., Parodi A.L. and Couvreur P. (1989) Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Select. Cancer Ther. 5: 1-11
46. Chiannikulchai N., Ammoury N., Caillou B., Devissaguet J.-P. and Couvreur P. (1990) Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in M5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 26: 122-126
47. Soma C.E., Dubernet C., Barratt G., Nemati F., Appel M., Benita S. et al. (1999) Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm. Res. 16: 1710-1716
48. Colin de Verdière A., Dubernet C., Nemati F., Soma E., Appel M., Ferté J. et al. (1997) Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: mechanism of action. B. J. Cancer 76: 198-205
49. Hartsel S. and Bolard J. (1996) Amphotericin B: new life for an old drug. Trends Phannacol. Sci. 17: 445-449
50. Wasan K. M. and Lopez-Berestein G. (1997) Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur. J. Clin. Microb. Infect. Dis. 16: 81-92
51. Yardley V. and Croft S. L., (1997)Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41: 752-756
52. Larabi M., Legrand P., Appel M., Gil S., Lepoivre M., Devissaguet J. P. et al. (2001) Reduction of NO synthase expression and TNF alpha production in macrophages by amphotericin B lipid carriers. Antimicrob. Agents Chemother. 45: 553-562
53. Hockertz S., Franke G., Kniep E. and Lohman-Matthes M. L. (1989) Mouse interferon-γ in liposomes: pharmacokinetics, organ distribution and activation of spleen and liver macrophages in vivo. J. Interferon Res. 9: 591-602
54. Kedar E., Gur H., Babai I., Samira S., Even-Chen S. and Barenholz Y. (2000) Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and long-circulating liposomes. J. Immunother. 23: 131-145
55. Chapat S., Frey V., Claperon N., Bouchaud C., Puisieux F., Counreur P. et al. (1992) Efficiency of liposomal ATP in cerebral ischemia: bioavailability features. Brain Res. Bull. 26: 339-342
56. Damgé C., Michel C., Aprahamiam M., Couvreur P. and Devissaguet J.-P. (1990) Nanocapsules as carriers for oral peptide delivery. J. Control. Rel. 13: 233-239
57. Damgé C., Vranckx H., Baldschmidt P. and Couvreur P. (1997) Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86: 1403-1409
58. Aboubakar M., Couvreur P., Pinto-Alphandary H., Gouritin B., Lacour B., Farinotti R. et al. (2000) Insulin-loaded nanocapsules for oral administration: in vitro and in vivo investigation. Drug Dev. Res. 49: 109-117
59. Damgé C., Vonderscher J., Marbach P. and Pinget M. (1997) Poly(alkylcyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J. Pharm. Pharmacol. 49: 949-954
60. Dembri A., Montisci M.-J., Gantier J.-C., Chacun H. and Ponchel G. (2001) Targeting of 3′ azido 3′ deoxythymidine (AZT) loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. 18: 467-473
61. Mathiowitz E., Jacob J. S., Jong Y. S., Carino G. P., Chickering D. E., Chaturredi P. et al. (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386: 410-414
62. Guterres S. S., Fessi H., Barratt G., Puisieux F. and Devissaguet J.-P. (1995) Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm. Res. 12: 1545-1547
63. Ammoury N., Fessi H., Devissaguet J-.P., Dubrasquet M. and Benita S. (1991) Jejunal absorption, pharmacological activity and pharmacokinetic evaluation of indomethacin-loaded poly(D,L-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm. Res. 8: 101-105
64. Ammoury N., Fessi H., Devissaguet J.-P., Allix M., Plotkine M. and Boulu R. G. (1990) Effect on cerebral blood flow of orally administered indomethacin-loaded poly(isobutylcyanoacrylate) and poly(D,L-lactide) nanocapsules. J. Pharm. Pharmacol. 42: 558-561
65. Fawaz F., Bonini F., Guyot M., Lagueny A. M., Fessi H. and Devissaguet J.-P. (1996) Disposition and protective effect against irritation after intravenous and rectal administration of indomethacin loaded nanocapsules to rabbit. Int. J. Pharm. 133: 107-115
66. Allaoui-Attarki K., Fattal E., Pecquet S., Trollé S., Chachaty E., Couvreur P. et al. (1998) Mucosal immunogenicity elicted in mice by oral vaccination with phosphorylcholine encapsulated in poly(D,L-lactide-co-glycolide) microspheres. Vaccine 16: 685-691
67. Roy K., Mao H. Q., Huang S. K. and Leong K. W. (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5: 387-391
68. Weiner N., Williams N., Birch G., Ramachandran C., Shipman C. Jr and Flynn G. (1989) Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea-pig model. Antimicrob. Agents Chemother. 33: 1217-1221
69. Losa C., Marchal-Heussler L., Orallo F., Vila Jato J. L. and Alonso M. J. (1993) Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm. Res. 10: 80-87
70. Calvo P., Sanchez A., Martinez J., Lopez Calonge M. I., Pastor J. C.and Alonso M. J. (1996) Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm. Res. 13: 311-315
71. Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J. L. and Alonso M. J. (1999) Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 16: 1576-1581
72. Konno H., Tadakuma T., Kumai K., Takahashi T., Ishibiki K., Abe O. et al. (1990) The antitumor effects of adriamycin entrapped in liposomes on lymph node metastases. Jpn. J. Surg. 20: 424-428
73. 14C] cytosine β-D-arabinofuranoside following intraperitoneal administration to rats. Drug. Metab. Dis. 10: 40-46
74. Phillips W. T., Klipper R. and Goins B. (2000) Novel method of greatly enhanced delivery of liposomes to lymph nodes. J. Pharmacol. Exp. Ther. 295: 309-313
75. Guterres S. S., Fessi H., Barratt G., Puisieux F. and Devissaguet J.-P. (2000) Poly(D,L-lactide) nanocapsules containing diclofenac: protection from muscular damage in rats. J. Biomater. Sci. - Polymer Ed. 11: 1347-1355
76. Lambert G., Bertrand J. R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C. et al. (2000) EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279: 401-406
77. Ishida O., Maruyama K., Yanagie H., Eriguchi M. and Iwatsuru M. (2000) Targeting chemotherapy to solid tumors with long-circulating thermosensitive liposomes and local hyperthermia. Jpn. J. Cancer Res. 91: 118-126
78. Allen T. M. and Chonn A. (1987) Large unilamellar liposomes with low uptake into the reticulo-endothelial system. FEBS Lett. 223: 42-46
79. Woodle M. C. (1998) Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug Deliv. Rev. 32: 139-152
80. Jeon S. I., Lee J. H., Andrade J. D. and De Gennes P. G. (1991) Protein-surface interactions in the presence of polyethylene oxide. 1. Simplified theory. J. Colloid. Interf. Sci. 142: 149-166
81. Gabizon A., Catane R., Uziely B., Kaufman B. and Barenholz Y. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubucin encapsulated in polyethylene-glycol-coated liposomes. Cancer Res. 54: 987-992
82. Allen T. M., Lopes de Menezes D., Hansen C. B. and Moase E. H. (1998) Stealth™ liposomes for the targeting of drugs in cancer. In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems, pp. 67-75, Gregoriadis G. and McCormack B. (eds), Plenum, New York
83. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br. J. Cancer 83: 232-238
84. Illum L., Jacobsen L. O., Müller R. H., Mak R. and Davis S.S. (1987) Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 8: 113-117
85. Gref R., Domb A., Quellec P., Blunk T., Müller R. H., Verbavatz J. M. et al. (1995)The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16: 215-233
86. Bazile D., Prud'Homme C., Bassoulet, M.-T. Marlard M., Spenlehauer G. and Veillard M. (1995) Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84: 493-498
87. Norman M. E., Williams P. and Illum L. (1993) Influence of block co-polymers on the adsorption of plasma proteins to microspheres. Biomaterials 14: 193-202
88. Moghimi S. M., Muir I., Illum L., Davis S. and Kolb-Bachofen V. (1993) Coating particles with a block copolymer (poloxamine 908) suppresses opsonisation but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta 1179: 157-165
89. Dunn S. E., Coombes A. G. A., Garnett M. C., Davis S. S., Davies M.C. and Illum L. (1997) In vitro interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J. Control. Release 44: 65-76
90. Stolnik S., Dunn S. E., Garnett M. C., Davies M. C., Coombes A. G. A., Taylor D. C. et al. (1994) Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 11: 1800-1808
91. Lenaerts V., Labib A., Chouinard F., Rousseau J., Ali H. and Lier. J. van (1995) Nanocapsules with a reduced liver uptake: targeting of phthalocyanines to EMT-6 mouse mammary tumour in vivo. Eur. J. Pharm. Biopharm. 41: 38-43
92. Quellec P., Gref P., Pervun L., Dellacherie E., Sommer F., Verbavatz Y. M. et al. (1998) Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J. Biomed. Mater. Res. 42: 45-54
93. Peracchia M.T., Desmaële D., Vauthier C., Labarre D., Fattal E. et al. (1998) Development of novel technologies for the synthesis of biodegradable pegylated nanoparticles. In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems, pp. 222-239, Gregoriadis G. and McCormack B. (eds), Plenum, New York
94. Brigger I., Chaminade P., Marsaud V., Appel M., Besnard M., Gurny R. et al. (2001) Tamoxifen encapsulation within polyethylene glycol-coated nanospheres: a new antiestrogen formulation. Int. J. Pharm. 214: 37-42
95. Mosqueira V. C. F., Legrand P., Gulik A., Bourdon O., Gref R., Labarre D. et al. (2001) Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22: 2967-2979
96. Mosqueira V. C. F., Legrand P., Gref R., Heurtault B., Appel M. and Barratt G. (1999) Interactions between a macrophage cell line (J774A1) and surface-modified poly(D,L-lactide) nanocapsules bearing poly(ethylene glycol). J. Drug Target. 7: 65-78
97. Mosqueira V. C. F., Legrand P., Gulik A., Bourdon O., Gref R., Labarre D. et al. (2001) Biodistribution of novel long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res. 18: 1411-1419
98. Gregoriadis G., Fernandes A., McCormack B., Mital M. and Zhang X. (1998) Polysialic acids: potential for long circulating drug, protein, liposome and other microparticle constructs. In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems, pp. 193-205, Gregoriadis G. and McCormack B. (eds), Plenum, New York
99. Passirani C., Ferrarini L., Barratt G., Devissaguet J.-P. and Labarre D. (1999) Preparation and characterization of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J. Biomater. Sci. Polymer Ed. 10: 47-62
100. Passirani C., Barratt G., Devissaguet J.-P. and Labarre D. (1998) Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci. 62: 775-778
101. Jaulin N., Appel M., Passirani C., Barratt G. and Labarre D. (2000) Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J. Drug Target. 8: 165-172
102. Passirani C., Barratt G., Devissaguet J.-P. and Labarre D. (1998) Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res. 15: 1046-1050
103. Chauvierre C., Couvreur P., Labarre D. and Vauthier C. (2000) Copolymère à structure séquencée composé d'un segment saccharidique et d'un segment hydrophobe bioérodable et nanoparticules correspondantes. Demande de brevet français No. 00 14900
104. Jain R. K. (1987) Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6: 559-593
105. Woodle M. C., Storm G., Neuman M. S., Jekot J. J., Collins L. R., Martin F. J. et al. (1992) Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharm. Res. 9: 260-265
106. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A. G. and Ithakissios D. S. (2002) PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release 79: 123-135
107. Mosqueira V. C. F., Legrand P., Bodes C., Devissaguet J.-P. and Barratt G. (2000) Comparative pharmacokinetics and in vivo efficacy of an intravenous formulation of halofantrine in long-circulating nanocapsules in Plasmodium berghei-infected mice. In: Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials, pp 490-491, Controlled Release Society Inc., Deerfield, Ill.
108. Lopes de Menezes D., Pilarski L. and Allen T. M. (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58: 3320-3330
109. Bourdon O., Mosqueira V., Legrand P. and Blais J. (2000) A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells. J. Photochem. Photobiol. B 55: 164-171
110. Oyen, W.J., Boerman O. C., Storm G., Bloois L. van, Koenders E. B., Crommelin D. J. et al. (1996) Labeled Stealth™ liposomes in experimental infection: an alternative to leukocyte scintigraphy? Nuclear Med. Commun. 17: 742-748
111. Schiffelers R. M., Bakker-Woudenberg I. A. and Storm G. (2001) Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene) glycol coating. Biochim. Biophys. Acta 1468: 253-261
112. Awasthi V., Goins B., Klipper R., Loredo R., Korvick D. and Phillips W. T. (1998) Imaging experimental osteomyelitis using radiolabeled liposomes. J. Nuclear Med. 39: 1089-1094
113. Oussoren C. and Storm G. (2001) Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 50: 143-156
114. Bochot A., Couvreur P. and Fattal E. (2000) Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res. 19: 131-147
115. Tobío M., Sánchez A., Vila A., Sociano I., Evora C., Vila-Jato J. L. et al. (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid. Surf. B Biointerf. 18: 315-323
116. Tobío M., Gref R., Sánchez A., Langer R. and Alonso M. J. (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 15: 270-275
117. Lasic D.D. (1997) Liposomes in Gene Therapy, CRC, Boca Raton
118. Fattal E., Nir S., Parente R. A. and Szoka F. C. Jr (1994) Pore-forming peptides induce rapid phospholipid flip-flop in membranes. Biochemistry 31: 6721-6731
119. Pecheur E. I., Hoekstra D., Sainte-Marie J., Maurin L., Bienvenüe A. and Philippot J. R. (1997) Membrane anchorage brings about fusogenic properties in a short synthetic peptides. Biochemistry 36: 3773-3781
120. De Oliveira M. C., Fattal E., Ropert C., Malvy C. and Couvreur P. (1997) Delivery of antisense oligonucleotides by means of pH-sensitive liposomes. J. Control. Release 48: 179-184
121. Mönkkönen J. and Urtti A. (1998) Lipid fusion in oligonucleotide and gene delivery with cationic lipids. Adv. Drug Del. Rev. 34: 37-49
122. Liu F. and Huang L. (2002) Development of non-viral vectors for systemic gene delivery. J. Control. Release 78: 259-266
123. Boussif O., Lezoualc'h F., Zanta M. A., Mergny M. D., Scherman D., Demeneix B. et al. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92: 7297-7301
124. Remy J.-S., Abdallah B., Zanta M. A., Boussif O., Behr J.-P. and Demeneix B. (1998) Gene transfer with lipospermines and polyethylenimines. Adv. Drug Deliv. Rev. 30: 85-95
125. Diebold S. S., Kursa M., Wagner E. , Cotten M. and Zenke M. (1999) Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. 274: 19087-19094
126. Guo W. and Lee R. J. (2001) Efficient gene delivery via noncovalent complexes of folic acid and polyethylenimine. J. Control. Release 77: 131-138
127. Kircheis R., Blessing T., Brunner S., Wightman L. and Wagner E. (2001) Tumor targeting with surface-shielded ligand-polycation DNA complexes. J. Control. Release 72: 165-170
128. Barbet J. (1995) Immunoliposomes. In: Liposomes: New Systems and New Trends in Their Applications, pp. 159-191, Puisieux F., Couvreur P., Delattre J. and Devissaguet J.-P. (eds), Editions de Santé, Paris
129. Mercadal M., Domingo J. C., Petriz J. C., Garcia, J. and De Madariaga M. M. (1999) A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface grafted PEG chains. Biochim. Biophys. Acta 1418: 232-238
130. Zalipsky S., Gittelman J., Mullah N., Qazen M. M. and Harding J. (1998) Biologically active ligand-bearing polymer-grafted liposomes. In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems, pp. 131-138, Gregoriadis G. and McCormack B. (eds), Plenum, New York
131. Barratt G. and Schuber F. (1993) Targeting of liposomes with mannose terminated ligands. In: Liposome Technology, 2nd edn, vol. III, pp 199-218, Gregoriadis G. (ed.), CRC, Boca Raton, Fla.
132. Barratt G. M., Nolibé D., Yapo A., Petit J.-F. and Tenu J.-P. (1987) Use of mannosylated liposomes for in vivo targeting of a macrophage activator and control of artificial pulmonary metastases. Ann. Inst. Pasteur (Immunol.) 138: 437-450
133. Vyas, S. P., Katare, Y. K., Mishra, V. and Sihorkar, V. (2000) Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int. J. Pharm. 210: 1-14
134. Agrawal A. J., Agrawal A., Pal A., Guru P. Y. and Gupta C. M. (2002) Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Drug. Target. 10: 41-45
135. Cho C.-S., Kobayashi A., Takei R., Ishihara T., Maruyama A., Akaike T. et al. (2001) Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. Biomaterials 22: 45-51
136. Shimada, K., Kamps J. A., Regts J., Ikeda K., Shiozawa T., Hirota S. et al. (1997) Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol). Biochim. Biophys. Acta 1326: 329-341
137. Yamamoto M., Ichinose K., Ishii N., Khoji T., Akiyoshi K., Moriguchi N. et al. (2000) Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells. Oncol. Rep. 7: 107-111
138. Scherphof G., Velinova M., Kamps J., Donga J., Want H. van der, Kuipers F. et al. (1997) Modulation of pharmacokinetic behavior of liposomes. Adv. Drug Deliv. Rev. 24: 179-191
139. Lopes de Menezes D. E., Pilarski L. M., Belch A. R. and Allen T. M. (2000) Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim. Biophys. Acta 1466: 205-220
140. Park J. W., Kirpotin D. B., Hong K., Shalaby R., Shao Y., Nielsen U. B. et al. (2001) Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 74: 95-113
141. Allen T. M. and Moase E. H. (1996) Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Deliv. Rev. 21: 117-133
142. Laverman P., Boerman O. C., Oyen W. J. G., Corstens F. H. M. and Storm G. (2001) In vivo applications of PEG liposomes: unexpected observations. Crit. Rev. Ther. Drug Carrier Syst. 18: 551-566
143. + leucocytes is dependent on immune status. J. Immunol. 152: 3168-3174
144. Szebeni J. (2001) Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug Carrier Syst. 18: 567-606
145. Cao Y. and Suresh M. R. (2000) Bispecific MAb aided liposomal drug delivery. J. Drug Target. 8: 257-266
146. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M. et al. (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18: 1042-1048
147. Eavarone D. A., Yu X. and Bellamkonda R. V. (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J. Biomed. Mater. Res. 51: 10-14
148. Derycke A. S. L. and De Witte P. A. M. (2002) Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int. J. Oncol. 20: 181-187
149. Wang, S. and Low, P. S. (1998) Folate-mediated targeting of antineoplastic drugs, imaging agents and nucleic acids to cancer cells. J. Control. Release 53: 39-48
150. Xu L., Pirollo K. F. and Chang E. H. (2001) Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release 74: 115-128
151. Stella B., Arpicco S., Peracchia M. T., Desmaële D., Hoebene J., Renoir M. et al. (2000) Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89: 1452-1464
152. Moreira J. N., Hansen C. B., Gaspar R. and Allen T. M. (2001) A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta 1514: 303-317
153. Otsubo, T., Maruyama K., Maesaki S., Miyazaki Y., Tanaka E., Takizawa T. et al. (1998) Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob. Agents Chemother. 42: 40-44
154. Mastrobattista E., Storm G., Bloois L. van, Reszka R., Bloernen P. G. M., Chrommelin D. J. A. et al. (1999) Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim. Biophys. Acta 1419: 353-363
155. Kessner S., Krause A., Rothe U. and Bendas G. (2001) Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells. Biochim. Biophys. Acta 1514: 177-190
156. Blackwell J. E., Dagia N. M., Dickerson J. B., Berg E. L. and Goetz D. J. (2001) Ligand coated nanosphere adhesion to E- and P-selectin under static and flow conditions. Ann. Biomed. Eng. 29: 523-533
157. Kamps J. A. A. M., Morselt H. W. M., Swart P. J., Meijer D. K. F. and Scherphof G. L. (1997) Massive targeting of liposomes, surface modified with anionized albumins, to hepatic endothelial cells. Proc. Natl. Acad. Sci. USA 94: 11681-11685
158. Patton W. A., Granzow C. A., Getts L. A., Thomas S. C., Zotter L. M., Gunzel K. A. et al. (1995) Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Biochem. J. 311: 461-469
159. Cansell M., Parisel C., Jozefonvicz J. and Letoumeur D. (1999) Liposomes coated with chemically modified dextrans interact with human endothelial cells. J. Biomed. Mater. Res. 44: 140-148
160. Letourneur D., Parisel C., Prigent-Richard S. and Cansell M. (2000) Interactions of functionalized dextran-coated liposomes with vascular smooth muscle cells. J. Control. Release 65: 83-91
161. Lestini B. J., Sagnella S. M., Yu Z., Shive M. S., Richter N. J., Jayaseharan J. et al. (2002) Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Control. Release 78: 235-247
162. Khaw B. A., Torchilin V. P., Vural I. and Narula J. (1995) Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat. Med. 1: 1195-1198
163. Benzinger P., Martiny-Baron G., Reusch P., Siemeister G., Kley J. T., Marné D. et al. (2000) Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. Biochim. Biophys. Acta 1466: 71-78
164. Pardridge W. M. (1999) Vector-mediated drug delivery to the brain. Adv. Drug Deliv. Rev. 36: 299-321
165. Shi N., Boado R. J. and Pardridge W. M. (2001) Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18: 1091-1095